Bibliography
- NO AUTHORS LISTED: RAPTIVA® (efalizumab) package insert. South San Francisco, CA: Genentech, Inc. (2005).
- LEBWOHL M, TYRING SK, HAMILTON TK et al.; EFALIZUMAB STUDY GROUP: A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N. Engl. J. Med. (2003) 349:2004-2013.
- MENTER A, GORDON K, CAREY W et al.: Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch. Dermatol. (2005) 141:31-38.
- GORDON KB, PAPP KA, HAMILTON TK et al.; EFALIZUMAB STUDY GROUP: Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA (2003) 290:3073-3080. Erratum in: JAMA (2004) 291:1070.
- GOTTLIEB AB, GORDON KB, LEBWOHL MG et al.; EFALIZUMAB STUDY GROUP: Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J. Drugs Dermatol. (2004) 3:614-624.
- LEONARDI CL, PAPP KA, GORDON KB et al.; EFALIZUMAB STUDY GROUP: Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized Phase III trial. J. Am. Acad. Dermatol. (2005) 52:425-433.
- GOTTLIEB AB, MILLER B, LOWE N et al.: Subcutaneously administered efalizumab (anti-CD11a) improves signs and symptoms of moderate to severe plaque psoriasis. J. Cutan. Med. Surg. (2003) 7:198-207.
- GAUVREAU GM, BECKER AB, BOULET LP et al.: The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma. J. Allergy Clin. Immunol. (2003) 112:331-338.
- LEONARDI CL, GOFFE B, SOBELL J et al.: The safety of efalizumab in patients with moderate to severe plaque psoriasis: summary of clinical trial experience. Presented at: 62nd Annual Meeting of the American Academy of Dermatology, Washington, DC (2004). Poster 613.
- MORSE LG, YARBROUGH L, HOGAN DJ: Cervical cancer in a woman associated with long-term efalizumab therapy. J. Am. Acad. Dermatol. (2005) 53:354-355.
- CATHER JC, MENTER A, VUGMEYSTER Y et al.: Efalizumab (anti-CD11a)-induced increase in leukocyte numbers in psoriasis patients is preferentially mediated by blocked entry of memory CD8+ T cells into the skin. Clin. Immunol. (2004) 113:38-46.
- GAYLOR ML, DUVIC M: Generalized pustular psoriasis following withdrawal of efalizumab. J. Drugs Dermatol. (2004) 3:77-79.
- LOWES MA, TURTON JA, KRUEGER JG, BARNETSON RS: Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series. BMC Dermatol. (2005) 5:9.
- TURNER J: Efficacy and safety of efalizumab therapy in two pediatric patients with plaque psoriasis Presented at: 63nd Annual Meeting of the American Academy of Dermatology, Washington, DC (2005). Poster 2747.
- GOTTLIEB A, LIZZUL P: Safety and efficacy of efalizumab therapy for elderly patients with moderate to severe chronic plaque psoriasis. Presented at: 63nd Annual Meeting of the American Academy of Dermatology, Washington, DC (2005). Poster 2791.
- HAMILTON TK: Clinical considerations of efalizumab therapy in patients with psoriasis. Semin. Cutan. Med. Surg. (2005) 24:19-27.
- CATHER J, MENTER A, YOUNG M, WIATROWSKI M: The use of efalizumab in the clinic. Presented at: 63nd Annual Meeting of the American Academy of Dermatology, Washington, DC (2005). Poster 2810.
- MORTENSEN DL, WALICKE PA, WANG X et al.: Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasis. J. Clin. Pharmacol. (2005) 45:286-298.
Website
- www.medpagetoday.com/ProductAlert/Prescriptions/tb/1393 Medpage Today website. Raptiva label to include hemolytic anemia warning (2005).